Literature DB >> 25538269

Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacment therapy.

Shilpa Sharma1, Carlo Brugnara2, Rebecca A Betensky3, Sushrut S Waikar4.   

Abstract

BACKGROUND AND OBJECTIVES: Hypophosphatemia is a frequent complication during continuous renal replacement therapy (CRRT), a dialytic technique used to treat AKI in critically ill patients. This study sought to confirm that phosphate depletion during CRRT may decrease red blood cell (RBC) concentration of 2,3-diphosphoglycerate (2,3-DPG), a crucial allosteric effector of hemoglobin's (Hgb's) affinity for oxygen, thereby leading to impaired oxygen delivery to peripheral tissues. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Phosphate mass balance studies were performed in 20 patients with severe AKI through collection of CRRT effluent. RBC concentrations of 2,3-DPG, venous blood gas pH, and oxygen partial pressure required for 50% hemoglobin saturation (P50) were measured at CRRT initiation and days 2, 4, and 7. Similar measurements were obtained on days 0 and 2 in a reference group of 10 postsurgical patients, most of whom did not have AKI. Associations of 2,3-DPG with laboratory parameters and clinical outcomes were examined using mixed-effects and Cox regression models.
RESULTS: Mean 2,3-DPG levels decreased from a mean (±SD) of 13.4±3.4 µmol/g Hgb to 11.0±3.1 µmol/g Hgb after 2 days of CRRT (P<0.001). Mean hemoglobin saturation P50 levels decreased from 29.7±4.4 mmHg to 26.7±4.0 mmHg (P<0.001). No significant change was seen in the reference group. 2,3-DPG levels after 2 days of CRRT were not significantly lower than those in the reference group on day 2. Among patients receiving CRRT, 2,3-DPG decreased by 0.53 µmol/g Hgb per 1 g phosphate removed (95% confidence interval 0.38 to 0.68 µmol/g Hgb; P<0.001). Greater reductions in 2,3-DPG were associated with higher risk for death (hazard ratio, 1.43; 95% confidence interval, 1.09 to 1.88; P=0.01).
CONCLUSIONS: CRRT-induced phosphate depletion is associated with measurable reductions in RBC 2,3-DPG concentration and a shift in the O2:Hgb affinity curve even in the absence of overt hypophosphatemia. 2,3-DPG reductions may be associated with higher risk for in-hospital death and represent a potentially avoidable complication of CRRT.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  acute renal failure; dialysis; mortality

Mesh:

Substances:

Year:  2014        PMID: 25538269      PMCID: PMC4284404          DOI: 10.2215/CJN.02160214

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  29 in total

1.  Gastric tonometry: the hemodynamic monitor of choice (Pro).

Authors:  Stephen O Heard
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

2.  Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters.

Authors:  Stéphan Troyanov; Jean Cardinal; David Geadah; Daniel Parent; Sylvie Courteau; Sylvie Caron; Martine Leblanc
Journal:  Nephrol Dial Transplant       Date:  2003-05       Impact factor: 5.992

3.  Red blood cell 2,3-diphosphoglycerate concentration and in vivo P50 during early critical illness.

Authors:  Ezz el din S Ibrahim; Stuart A McLellan; Timothy S Walsh
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

4.  Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.

Authors:  Glenn M Chertow; Elisabeth Burdick; Melissa Honour; Joseph V Bonventre; David W Bates
Journal:  J Am Soc Nephrol       Date:  2005-09-21       Impact factor: 10.121

5.  Amino acid losses during hemodialysis: effects of high-solute flux and parenteral nutrition in acute renal failure.

Authors:  E D Hynote; M A McCamish; T A Depner; P A Davis
Journal:  JPEN J Parenter Enteral Nutr       Date:  1995 Jan-Feb       Impact factor: 4.016

6.  Alterations of red-cell glycolytic intermediates and oxygen transport as a consequence of hypophosphatemia in patients receiving intravenous hyperalimentation.

Authors:  S F Travis; H J Sugerman; R L Ruberg; S J Dudrick; M Delivoria-Papadopoulos; L D Miller; F A Oski
Journal:  N Engl J Med       Date:  1971-09-30       Impact factor: 91.245

7.  Severe acute hypophosphatemia during renal replacement therapy adversely affects outcome of critically ill patients with acute kidney injury.

Authors:  Helmut Schiffl; Susanne M Lang
Journal:  Int Urol Nephrol       Date:  2012-01-07       Impact factor: 2.370

8.  Effect of decreased O2 affinity of hemoglobin on work performance during exercise in healthy humans.

Authors:  M O Farber; T Y Sullivan; N Fineberg; S Carlone; F Manfredi
Journal:  J Lab Clin Med       Date:  1984-08

Review 9.  Continuous renal replacement therapy in the treatment of acute renal failure: critical assessment is required.

Authors:  Jonathan Himmelfarb
Journal:  Clin J Am Soc Nephrol       Date:  2007-01-31       Impact factor: 8.237

10.  Regional citrate anticoagulation in CVVH: a new protocol combining citrate solution with a phosphate-containing replacement fluid.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Laura Zeppilli; Francesca Polistena; Enrico Fiaccadori; Alessandro Pierucci
Journal:  Hemodial Int       Date:  2012-08-07       Impact factor: 1.812

View more
  8 in total

1.  Intensity of Renal Replacement Therapy and Duration of Mechanical Ventilation: Secondary Analysis of the Acute Renal Failure Trial Network Study.

Authors:  Shilpa Sharma; Yvelynne P Kelly; Paul M Palevsky; Sushrut S Waikar
Journal:  Chest       Date:  2020-05-26       Impact factor: 9.410

2.  Staying on target with continuous dialysis.

Authors:  Sevag Demirjian; William H Fissell
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-23       Impact factor: 8.237

3.  IDEAL-ICU in Context.

Authors:  David E Leaf; Sushrut S Waikar
Journal:  Clin J Am Soc Nephrol       Date:  2019-07-17       Impact factor: 8.237

Review 4.  Hypophosphatemia in critically ill patients with acute kidney injury on renal replacement therapies.

Authors:  Valentina Pistolesi; Laura Zeppilli; Enrico Fiaccadori; Giuseppe Regolisti; Luigi Tritapepe; Santo Morabito
Journal:  J Nephrol       Date:  2019-09-12       Impact factor: 3.902

5.  Phosphate Dysregulation and Neurocognitive Sequelae.

Authors:  John Acquaviva; Hosam G Abdelhady; Mohammed S Razzaque
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Association of Phosphate-Containing versus Phosphate-Free Solutions on Ventilator Days in Patients Requiring Continuous Kidney Replacement Therapy.

Authors:  Melissa L Thompson Bastin; Arnold J Stromberg; Sethabhisha N Nerusu; Lucas J Liu; Kirby P Mayer; Kathleen D Liu; Sean M Bagshaw; Ron Wald; Peter E Morris; Javier A Neyra
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-27       Impact factor: 10.614

7.  CRRT Fluid Choices: A Solution for a Common Problem?

Authors:  Anitha Vijayan
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-27       Impact factor: 10.614

8.  Analysis of Red Blood Cells and their Components in Medical Workers with Occupational Exposure to Low-Dose Ionizing Radiation.

Authors:  Xue-Lei Tian; Xue Lu; Yu-Min Lyu; Hua Zhao; Qing-Jie Liu; Mei Tian
Journal:  Dose Response       Date:  2022-02-24       Impact factor: 2.658

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.